Alteration in glutamate neurotransmission has been found to mediate the development of drug dependence, including nicotine. We and others, through using western blotting, have reported that exposure to drugs of abuse reduced the expression of glutamate transporter-1 (GLT-1) as well as cystine/glutamate antiporter (xCT), which consequently increased extracellular glutamate concentrations in the mesocorticolimbic area. However, our previous studies did not reveal any changes in glutamate/aspartate transporter (GLAST) following exposure to drugs of abuse. In the present study, for the first time, we investigated the effect of chronic exposure to electronic (e)-cigarette vapor containing nicotine, for one hour daily for six months, on GLT-1, xCT, and GLAST expression in frontal cortex (FC), striatum (STR), and hippocampus (HIP) in outbred female CD1 mice. In this study, we also investigated the expression of alpha-7 nicotinic acetylcholine receptor (α-7 nAChR), a major pre-synaptic nicotinic receptor in the glutamatergic neurons, which regulates glutamate release. We found that inhalation of e-cigarette vapor for six months increased α-7 nAChR expression in both FC and STR, but not in the HIP. In addition, chronic e-cigarette exposure reduced GLT-1 expression only in STR. Moreover, e-cigarette vapor inhalation induced downregulation of xCT in both the STR and HIP. We did not find any significant changes in GLAST expression in any brain region. Finally, using liquid chromatography-tandem mass spectrometry (LC-MS/ MS) techniques, we detected high concentrations of nicotine and cotinine, a major metabolite of nicotine, in the FC tissues of e-cigarette exposed mice. These data provide novel evidence about the effects of chronic nicotine inhalation on the expression of key glial glutamate transporters as well as α-7 nAChR. Our work may suggest that nicotine exposure via chronic inhalation of e-cigarette vapor may be mediated in part by alterations in the glutamatergic system.
Introduction
Electronic (e)-cigarettes are battery operated nicotine delivery devices that heat and aerosolize e-liquid, creating vapor [For review (Hahn et al., 2014) ]. Most e-liquid on the market contains nicotine, thus users who are inhaling e-cigarette vapor are also inhaling nicotine (Crotty Alexander et al., 2015) . Recently, e-cigarette use has increased globally as an alternative or supplement to conventional tobacco cigarette use (Crotty Alexander et al., 2015; Schoenborn and Gindi, 2015; Yamin et al., 2010) . Emerging evidence demonstrates that exposure to e-cigarettes may induce several toxicological effects, including inflammation, decreased host defenses and DNA damage that is a precursor to neoplastic transformation (Hwang et al., 2016; Vardavas et al., 2012; Yu et al., 2016) .
Although e-cigarettes were invented as a smoking cessation tool, they have been demonstrated to confer similar urges to smoke, as compared to conventional smoking (King et al., 2014) . Withdrawal symptoms and high desire to smoke were associated with withholding of e-cigarettes (Dawkins et al., 2012) . E-cigarettes deliver smaller amounts of nicotine per puff as compared to tobacco cigarettes, however, similar systemic nicotine and cotinine concentrations to combustible cigarettes have been achieved after exposure (Schroeder and Hoffman, 2014) . It has been reported that some brands of ecigarettes can deliver higher nicotine levels as compared to combustible cigarettes (Ramôa et al., 2015) . Exposure to nicotine containing ecigarette vapor during late prenatal and early postnatal life induced significant persistent behavioral alterations during adulthood compared to vehicle control (e-cigarettes without nicotine) and air-control mice .
In the present study, we investigated the effects of chronic exposure to e-cigarette vapor containing nicotine, using a well-established, clinically relevant mouse exposure system, on the glutamatergic system in female CD-1 mice. The rationale for using female, not male, mice in this study is that previous studies found that female animal models showed higher nicotine seeking behavior compared to male models (Donny et al., 2000; Torres et al., 2009 ). In addition, a prior study found that female rats exhibited higher motivation to consume nicotine as compared to male and female ovariectomized rats (Donny et al., 2000) . This suggests that hormones, including estradiol, play a crucial role in nicotine seeking behavior. Moreover, nicotine rewarding effects have been enhanced in female rats as compared to male rats (Torres et al., 2009) .
Nicotinic acetylcholine receptors (nAChRs), including alpha-7 nAChR (α-7 nAChR), have been found to be upregulated or stimulated following exposure to nicotine (Alsharari et al., 2015; Auta et al., 2000; Buisson and Bertrand, 2001; Konradsson-Geuken et al., 2009 ). Importantly, α-7 nAChR is localized mainly in pre-synaptic glutamatergic neurons in the mesocorticolimbic areas (Feduccia et al., 2012; Jones and Wonnacott, 2004; Marchi et al., 2002) and this receptor has been found to modulate the majority of glutamate release in prefrontal cortex (PFC) and other brain regions following nicotine exposure (Bortz et al., 2013; Feduccia et al., 2012; Konradsson-Geuken et al., 2009) . However, there is little known about the effects of chronic nicotine exposure on α-7 nAChR expression. We here, for the first time, determined the expression of α-7 nAChR in frontal cortex (FC), striatum (STR) and hippocampus (HIP) following six months of inhalation of ecigarette vapor containing nicotine in female CD-1 mice.
Additionally, we and others have shown that chronic exposure to drugs of abuse reduced the expression of glutamate transporter-1 (GLT-1,) as well as cystine/glutamate antiporter (xCT) in the nucleus accumbens (NAc), HIP and amygdala (Aal-Aaboda et al., 2015; Alhaddad et al., 2014a; Alhaddad et al., 2014b; Knackstedt et al., 2009; Knackstedt et al., 2010) . It is important to note that GLT-1 is responsible for clearance of a majority of the extracellular glutamate concentration into astrocytes (Danbolt, 2001; Tanaka et al., 1997) . Decreased GLT-1expression was associated with significantly increased extracellular glutamate concentrations in the NAc in animals exposed to alcohol or heroin (Das et al., 2015; LaLumiere and Kalivas, 2008; Melendez et al., 2005; Shen et al., 2014) . In addition, xCT plays a crucial role in glutamate homeostasis by exchanging extracellular cystine for intracellular glutamate (Baker et al., 2002; Shih et al., 2006) . Moreover, the xCT system was found to be involved in attenuation of nicotine seeking (Knackstedt et al., 2009) . Glutamate/ aspartate transporter (GLAST) is another glutamate transporter, colocalized with GLT-1 in astrocytes, and is mainly expressed in the cerebellum and retina (Danbolt, 2001; Lehre and Danbolt, 1998 ). Although we did not observe any downregulation in GLAST expression following alcohol drinking for five weeks (Alhaddad et al., 2014b; Hakami et al., 2016) , we aimed in this study to determine whether chronic nicotine exposure may affect the expression of this glial glutamate transporter in the central reward brain regions. In the present study, the expression of GLT-1, xCT, and GLAST after six months of exposure to e-cigarette vapor containing nicotine was investigated in the FC, STR and HIP.
Several studies have detected nicotine and cotinine (the major metabolite and biomarker of nicotine) in plasma and urine (Acosta et al., 2004; Chang et al., 2005; Curvall et al., 1982; Degen and Schneider, 1991; Hengen and Hengen, 1978; Horstmann, 1985; Levine et al., 2013; Mercelina-Roumans et al., 1996) . Few studies have assessed the concentration of nicotine and cotinine in specific brain regions, such as NAc and STR (Chang et al., 2005; Katner et al., 2015) . However, there is little known about the bioavailability of nicotine in the brain following six months of inhalation of e-cigarette vapor. As compared to other routes of administration, nicotine inhalation has a fast and high rate of absorption as well as high rate of brain distribution [For review see (Le Houezec, 2003) ]. Detection of high concentrations of nicotine and cotinine in the brain during chronic nicotine inhalation might suggest the degree of nicotine exposure associated with any changes in the glutamatergic system. In this study, Western blotting was used to quantify changes in the amount of proteins that are expressed in neurons and glia in different brain regions for air control and e-cigarette vapor containing nicotine groups. In addition, we determined nicotine and cotinine concentrations in the FC following six months of exposure to e-cigarette vapor.
Materials and methods

E-cigarettes
All e-cigarette atomizers (tanks; 2.4 Ω, plastic, refillable) and eliquids (propylene glycol, vegetable glycerin, nicotine, with no additives) used in the study were bought online from Xtreme Vaping. Eliquids were prepared in the lab by mixing 50% propylene glycol, 50% vegetable glycerin, and 24 mg/mL nicotine. This composition is commonly used in multiple brands of e-cigarettes as well as with users who make their own e-cigarettes. E-cigarette batteries (280 mAh fixed, automatic, rechargeable, stainless steel) were purchased online from FastTech. Fresh e-cigarette vapor was used for all murine exposures, as described previously (Hwang et al., 2016) . Briefly, voltage was applied to the heating coil in the e-liquid for 4 s every 20 s, and at the same time 2 L/min negative pressure was applied to draw the e-liquid through the atomizer, creating the e-cigarette vapor.
Mouse inhalation of e-cigarette vapor
Six week old, female CD-1 mice were obtained from Jackson Labs. CD-1 mice are outbred, and thus have higher genetic diversity than most mouse lines. Significant findings in this mouse line are thought to have more clinical relevance, as their genetic diversity leads to more heterogeneity in the results, requiring a more powerful signal to reach significance. The inExpose system (SciReq) was used as previously described (Hwang et al., 2016) to provide nose-only e-cigarette vapor for inhalation, thus limiting the exposure to the respiratory system. Both e-cigarette and control mice are placed into the soft-mesh inExpose restraints for 60 min per day, five days per week, but the control mice breath room air only. At the age of 7-8 weeks, e-cigarette mice were exposed to e-cigarette vapor containing 24 mg/mL nicotine for 12 s/min, for 60 min/day, five days per week, for six months (Drummond et al., 2016; Hwang et al., 2016; Smith et al., 2015) . Control mice were placed in the same restraints, but breathed room air only (Air control group). To create appropriate experimental controls, air control and e-cigarette exposed mice were placed into identical, individual mesh restraints. Although the air control group was intended to only breathe air, they were placed into the same hood as the e-cigarette mice attached to the InExpose device, to ensure similar temperature, light and sound exposures. Mice were allowed to recover for 30 min in pre-warmed cages following restraint. Mice were euthanized 1-2 h after the last treatment with terminal intracardiac bleeding, under general anesthesia [100 mg/kg ketamine (Zoetis) and 10 mg/kg xylazine (Vedco)]. Note all animals were used in accord with the NIH guidelines for animal use under protocols approved by the IACUC committee at the University of California, San Diego and San Diego VA health system.
Brain tissue harvesting
Brains were gently removed from the skull. Specific brain regions, including FC, STR and HIP, were dissected according to stereotaxic coordinates from the Mouse Brain Atlas (Paxinos, 2007) . Brain sections were immediately snap frozen in liquid nitrogen and stored at −80°C for immunoblot testing.
Western blot protocol for detection of α-7 nAChR, GLT-1, xCT and GLAST
Western blotting was used to quantify changes in the expression of α-7 nAChR, GLT-1, xCT, GLAST and GAPDH in FC, STR and HIP tissues between e-cigarette and air control groups, as described previously (Alasmari et al., 2015; Alasmari et al., 2016a; Hakami et al., 2016) . Brain tissues (FC, STR and HIP) were homogenized in lysis buffercontaining protease inhibitors. Total protein in each homogenized brain sample was quantified using Bio-Rad quantification reagents, DC™ (detergent compatible) protein assay (Bio-Rad, Hercules, CA, USA). Equal amounts of protein from FC, STR, and HIP tissue samples were loaded on 10-20% polyacrylamide gels for electrophoretic separation. Proteins were transferred to PVDF membranes, which were blocked using 5% (α-7 nAChR) or 3% (GLT-1, xCT, GLAST and GAPDH) milk in Tris-buffered saline with Tween-20 (TBST) for 30 min at room temperature. Membranes were incubated at 4°C overnight with one of the following primary antibodies: rat anti-α-7 nAChR (1:500 Abcam), guinea pig anti-GLT-1 (1:5000 Millipore), rabbit anti-xCT (1:1000 Abcam), and rabbit anti-GLAST (1:5000 Abcam). Mouse anti-GAPDH (1:5000 Millipore) was used as the loading control. On the following day, the membranes were washed with TBST and blocked with 3% milk in TBST for 30 min at room temperature, followed by incubation with horseradish peroxidase-labeled (HRP) secondary antibodies (anti-rat IgG, anti-guinea pig IgG, anti-rabbit IgG or anti-mouse IgG) at 1:3000 for 90 min. The membranes were washed five times with TBST and dried. Chemiluminescence was detected using a commercially available kit (Super Signal West Pico, Pierce Inc.) applied to the dried membranes for one minute prior to exposure. An SRX-101A processor was used to develop the radiographic films (HyBlot CL Film Thermo Fisher Scientific) that were exposed to membranes incubated with chemiluminescence reagent. The digitized images of the α-7 nAChR, GLT-1, xCT, GLAST and GAPDH bands were quantified and assessed using MCID software. The data obtained from air control animals were used as 100% to focus on changes in the expression of studied proteins in brain regions of animals exposed to e-cigarette vapor containing nicotine.
2.5. Quantitation of nicotine and cotinine via ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS)
As described below, a portion of the FC was spiked with extraction buffer containing LC-MS internal standards, homogenized, extracted using a solid phase resin, and analyzed using LC-MS/MS via multiple reaction monitoring (MRM) to quantitate nicotine and cotinine. Treatment duration, route, conditions, and identity of samples were blinded to the LC-MS experimenter. Briefly, FC tissue (10-30 mg [n = 12]) was weighed and transferred to a 1.5 mL RINO tube (Next Advance Inc.) followed by addition of tissue extraction reagent (100 μL Cambridge Isotopes). UPLC utilized a Kinetex-core column (Phenomenex): 2.6 um C18 100 Å, 100 × 4.6 mm. UPLC Method: aqueous ammonium acetate (10 mM, solvent A); methanolic Ammonium Acetate (10 mM, solvent B); flow rate 1.0 mL/min (utilized post-column T-split, MS effective flow-rate = 0.3 mL/min). Gradient: t = 0 min, 0% B; t = 4 min, 95% B; t = 5.50 min, 95% B; t = 5.51, 0% B. Stop time 10 min. The resulting total ion chromatograms (TIC) for each MRM event demonstrated parent ion transition to three qualified fragment ions and were integrated to determine the area under the curve (AUC) of each analyte in each sample. Quantitation was carried out using a calibration curve and the ratio of the AUC of each analyte peak with the corresponding internal standard (AUC Nic /AUC Nicd4 and AUC Cot /AUC Cotd3 ) (Fig. 5) .
Forebrain tissue was spiked with varying concentrations of each analyte (Nicotine and Cotinine at 0.05, 0.1, 1, 5, and 10 μM) and processed as described for experimental samples above. A calibration curve was generated and extraction efficiency calculated based on the ratio of the AUC of the analyte peak to the AUC of the corresponding internal standard peak. The calibration curve was used to calculate concentration of analytes after normalization according to the weight of FC tissue used in each instance. Cotinine levels in serum were assessed via cotinine ELISA (Calbiochem), following the standard protocol and using a standard curve.
Statistical analyses
Western blot data obtained for proteins of interest in FC, STR and HIP tissues between e-cigarette and air control groups were analyzed using an independent unpaired t-test. The densities of immunoblot bands from the air control group were defined as 100%. LC-MS data analyses used one-way ANOVA with Tukey's post-test. All statistical analyses were represented as a p < 0.05 level of significance.
Results
Effects of e-cigarettes on α-7 nAChR expression in the FC, STR and HIP
We determined the expression of α-7 nAChR following six months of e-cigarette vapor inhalation in the FC, STR and HIP. Unpaired t-test analyses showed an increase in the expression of α-7 nAChR in both FC (p < 0.01; Fig. 1 ) and STR (p < 0.05; Fig. 1) in the e-cigarette group as compared to air controls. However, unpaired t-test analyses did not show any changes in α-7 nAChR in HIP (p > 0.05; Fig. 1 ).
Effects of e-cigarettes on GLT-1 expression in the FC, STR and HIP
We investigated the effects of chronic e-cigarette use on the expression of GLT-1 in FC, STR and HIP brain regions. E-cigarette vapor inhalation reduced GLT-1 expression in the STR significantly, as compared to air controls (p < 0.05; Fig. 2 ). However, six months of exposure to e-cigarettes did not induce significant alterations in GLT-1 expression in either the FC or HIP (p > 0.05; Fig. 2 ).
Effects of e-cigarettes on xCT expression in the FC, STR and HIP
We further investigated the expression of xCT after six months of exposure to e-cigarettes. As compared to the air control group, unpaired t-test analyses showed significantly decrease in the expression of xCT in the STR (p < 0.05; Fig. 3 ) and HIP (p < 0.01; Fig. 3 ) in e-cigarette vapor exposed mice. However, e-cigarette vapor inhalation for six months did not cause any changes in xCT expression in the FC (p > 0.05; Fig. 3 ).
Effects of e-cigarettes on GLAST expression in the FC, STR and HIP
The effects of nicotine containing e-cigarette vapor inhalation for six months on GLAST expression in the FC, STR and HIP were determined. Independent t-test analyses did not reveal any changes in GLAST expression in any of the three brain regions (p > 0.05; Fig. 4) . Fig. 1 . Effects of six months exposure to e-cigarette vapor (e-Cig) containing nicotine on α-7 nAChR expression in the FC, STR and HIP in female CD-1 mice. A) Immunoblot bands for α-7 nAChR and GAPDH (loading control) expression in the FC, STR and HIP. B) Unpaired t-test analysis of immunoblots showed a significant increase in the ratio of α-7 nAChR/GAPDH in FC and STR, but not in HIP, in e-cigarette exposed mice as compared with air controls (control value set to 100%). Data are shown as mean ± SEM (**p < 0.01; *p < 0.05), (n = 4-5 for each group). Fig. 2 . Effects of six months of inhalation of e-cigarette vapor containing nicotine (e-Cig) on GLT-1 expression in the FC, STR and HIP in female CD-1 mice. A) Immunoblot bands for GLT-1 and GAPDH (loading control) expression in the FC, STR and HIP. B) Unpaired ttest analysis of immunoblots showed a significant decrease in the ratio of GLT-1/GAPDH in STR, and not significant in FC and HIP, in e-cigarette exposed mice compared with air controls (control value set to 100%). Data are shown as mean ± SEM (*p < 0.05), (n = 4-5 for each group). Fig. 3 . Effects of six months e-cigarette vapor containing nicotine inhalation (e-Cig) on xCT expression in the FC, STR and HIP of female CD-1 mice. A) Immunoblot bands for xCT and GAPDH (loading control) expression in FC, STR and HIP tissues. B) Unpaired ttest analysis of immunoblots showed a significant decrease in the ratio of xCT/GAPDH in STR and HIP, but not significant in FC, in e-cigarette mice as compared with air controls (control value set to 100%). Data are shown as mean ± SEM (**p < 0.01; *p < 0.05), (n = 4-5 for each group). Fig. 4 . Effects of six months e-cigarette vapor containing nicotine inhalation (e-Cig) on GLAST expression in the FC, STR and HIP. A) Immunoblot bands for GLAST and GAPDH (loading control) expression in FC, STR and HIP tissues. B) Unpaired t-test analysis of immunoblots showed non-significant changes in the ratio of GLAST/GAPDH in FC, STR and HIP in e-cigarette exposed mice as compared with air controls (control value set to 100%). Data are shown as mean ± SEM, (n = 4-5 for each group).
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Determination of nicotine and cotinine concentrations in the FC, and cotinine in the plasma
Nicotine and cotinine concentrations were determined quantitatively using LC-MS based on a calibration curve correlating the area under the curve relationship of isotope labeled analytical standards (Nicotine-d 4 and Cotinne-d 3 ) at fixed concentrations with varying concentrations of nicotine and cotinine (Fig. 5A ). Nicotine and cotinine were both found in the FC at significant levels in e-cigarette exposed mice, 18.82 μM ( ± 3.7) and 16.65 μM ( ± 9.2), respectively (Fig. 5B,C,D) . The relatively short biological half-life of nicotine (reported at~10-30 min), makes our finding of significant interest. It suggests that chronic e-cigarette use could result in accumulation of nicotine and its chief metabolite, cotinine, in the FC. Cotinine has a 16 h half-life in vivo, therefore it has more stable levels over time as compared to nicotine, making it an ideal biomarker for daily nicotine intake via smoking and vaping (Hukkanen et al., 2005) . Cotinine in mouse plasma immediately after e-cigarette vapor exposure was 243 ± 14 ng/mL. Human cotinine levels are typically between 250 and 300 ng/mL in cigarette smokers (Benowitz et al., 1983; Gori and Lynch, 1985) . Nonsmokers exposed to secondhand smoke have serum cotinine levels of < 1 ng/mL, but heavy exposure can lead to levels of 1-10 ng/mL. Active smokers consistently have serum levels higher than 10 ng/mL, averaging in the 250-300 ng/mL range, and sometimes higher than 500-800 ng/mL in heavy tobacco users (Hukkanen et al., 2005) . Thus, our mouse e-cigarette exposure protocol leads to blood cotinine levels similar to that of smokers.
Discussion
Several studies have investigated the effects of nicotine on the glutamatergic system in different brain regions in the mesocorticolimbic areas (Kenny et al., 2009; Knackstedt et al., 2009; KonradssonGeuken et al., 2009; Wang et al., 2007) . Nicotine increases glutamate neurotransmission as well as upregulates post-synaptic glutamate receptor in these areas (Kenny et al., 2009; Konradsson-Geuken et al., 2009; Neff et al., 1998; Wang et al., 2007) . It has been reported that the PFC sends glutamatergic inputs into NAc, a major brain region in the ventral STR (Kalivas and Volkow, 2005) . In addition, the PFC sends as well as receives glutamatergic projections into and from the HIP (Gigg et al., 1994; Hyman et al., 1987; Parent et al., 2010) . Moreover, the HIP has been shown to send glutamatergic inputs into the NAc (Britt et al., 2012) . This glutamatergic interaction between different brain regions indicates the important role of the glutamatergic system following exposure to nicotine. In these studies, we investigated changes in the glutamatergic system, including nicotinic receptors, glutamate transporters and glutamate antiporters in FC, STR and HIP brain regions following six months of nicotine-containing e-cigarette vapor inhalation by female CD-1 mice. We designed our mouse e-cigarette vapor exposure system based on the most common conventional cigarette smoke exposure, which entails 1 s of cigarette smoke every 60 s for 1 h daily (1 min total of cigarette smoke). Users take longer drags from ecigarettes (3-4 s) as compared to conventional cigarettes (1 s), and have been found to consume more e-cigarette vapor daily when directly compared to cigarettes, thus our system activates the e-cigarette for 4 s, three times per minute. The total e-cigarette vapor exposure of one hour per day, 5 days per week, is modest compared to what heavy e-cigarette users are reporting. Alternatively, vapor inhalation for drug delivery has been well used in several drugs of abuse animal models. However, it is important to consider that vapor inhalation delivery may or not induce hormonal changes in animals as compared to animals exposed to drugs of abuse using different delivery routes. Studies are warranted to determine whether cigarette vapor inhalation can lead to hormonal changes in female and male animal models.
The effects of nicotine exposure on α-7 nAChR have been studied extensively (Alkondon and Albuquerque, 2005; Auta et al., 2000; Konradsson-Geuken et al., 2009; McGehee et al., 1995) . However, there is little known about the effects of chronic nicotine exposure on α-7 nAChR expression. Gutamatergic synaptic transmission has been enhanced at least in part by stimulatory effects of nicotine on presynaptic α-7 nAChR (Cheng and Yakel, 2014) . Stimulating α-7 nAChR by nicotine has been suggested to be one of the main mechanisms for nicotine-induced high extracellular glutamate concentrations in the mesocorticolimbic areas (Cheng and Yakel, 2014; Konradsson-Geuken et al., 2009) . Chronic exposure to nicotine was found to be associated with upregulation of post-synaptic glutamate receptors (Alasmari et al., 2016a; Kenny et al., 2009; Wang et al., 2007) and that the effect has been suggested to be associated with altered glutamate neurotransmis- F. Alasmari et al. Progress in Neuropsychopharmacology & Biological Psychiatry 77 (2017) 1-8 sion in the mesocorticolimbic brain regions (Wang et al., 2007) . Importantly, α-7 nAChR is expressed in glutamatergic projections from PFC to central brain reward regions such as NAc and ventral tegmental area (VTA) [For review see (Feduccia et al., 2012) ]. This indicates that α-7 nAChR, expressed in the PFC, mediates glutamatergic projections into NAc and VTA. In this study, we determined a significant increase in α-7 nAChR expression in the FC in e-cigarette exposed mice as compared to air controls (Fig. 1) . Moreover, we found that six months exposure to e-cigarettes upregulated α-7 nAChR in the STR as compared to air controls. It is important to note that, in a previous study, one minute local perfusion of nicotine (10 nmol/min) into the STR was able to upregulate α-7 nAChR significantly in Flinders Sensitive rats as compared to Flinders Resistant rats, which was associated with significant increases in dopamine concentrations (Auta et al., 2000) . Stimulation of α-7 nAChR in STR by a receptor agonist, through a microdialysis probe, induced glutamate release and, consequently, dopamine release (Campos et al., 2010) . These and our findings suggest that α-7 nAChR in STR may be critical in the development of nicotine dependence through stimulation of glutamate and dopamine release. A prior study reported that two subcutaneous nicotine injections in male rat pups at postnatal days 14 or 15 did not induce any upregulatory effects on α-7 nAChR expression in HIP slices (Alkondon and Albuquerque, 2005) . Our results also showed that α-7 nAChR expression in the HIP region is not changed following chronic (six month) inhalation of nicotine within e-cigarette vapor. It is important to note that α-7 nAChR is highly expressed in HIP (Clarke et al., 1985; Marks et al., 1996; Seguela et al., 1993) , which may suggest that neuroadaptation mediating α-7 nAChR expression in the HIP is a key factor that may reduce the effects of chronic nicotine exposure on the changes of the expression of this receptor.
The effects of drugs of abuse on GLT-1 and xCT have been investigated extensively (Alhaddad et al., 2014a; Alhaddad et al., 2014b; Hakami et al., 2016; Knackstedt et al., 2009; Knackstedt et al., 2010) . Our lab showed that chronic exposure to ethanol for five weeks reduced the expression of GLT-1 and xCT in NAc, HIP, and amygdala in male rats (Aal-Aaboda et al., 2015; Alhaddad et al., 2014b; Hakami et al., 2016) . In addition, β-lactam antibiotics and (R)-(−)-5-methyl-1-nicotinoyl-2-pyrazoline (MS-153) upregulated GLT-1 and xCT in these brain regions and consequently attenuated ethanol drinking behavior (Aal-Aaboda et al., 2015; Alasmari et al., 2015; Alasmari et al., 2016b; Alhaddad et al., 2014b) . Moreover, ceftriaxone, a β-lactam antibiotic, and N-acetylcysteine restored the expression of both GLT-1 and xCT in rats exposed to cocaine and consequently reduced relapse-like cocaine seeking behavior (Knackstedt et al., 2010) . GLT-1 and xCT have been suggested to play a crucial role in nicotine-seeking behavior such as nicotine-self administration and reinstatement of nicotine, as well as nicotine tolerance (Alajaji et al., 2013; Gipson et al., 2013; Knackstedt et al., 2009; Ramirez-Niño et al., 2013; Schroeder et al., 2011) . A recent study from our lab showed that ceftriaxone attenuated ethanol-, nicotine-, and a mixed solution of ethanol and nicotine-drinking behavior at least in part by upregulating GLT-1 in both NAc and PFC . Importantly, selfadministration of nicotine (0.03 mg/kg) base/infusion for 21 days induced down-regulatory effects on GLT-1 in NAc but not in other brain regions, including VTA, amygdala and PFC (Knackstedt et al., 2009) . The same study found that nicotine self-administration for 21 days reduced the expression of xCT in both NAc and VTA (Knackstedt et al., 2009) . In the present study, we used a model of nicotine intake with high physiological relevance to human e-cigarette users. We found that inhalation of e-cigarette vapor-containing nicotine for six months reduced GLT-1 expression in the STR but not in the FC and HIP. This suggests that GLT-1 protein in the STR is reduced following chronic nicotine exposure, and that this reduction may be due to the motivational effects of drugs of abuse, including nicotine (Knackstedt et al., 2009; Reissner and Kalivas, 2010) .
We report here a significant reduction in xCT expression in the STR and HIP but not in FC tissues in e-cigarette exposed mice as compared to air controls. It is important to note that in contrast to continuous exposure to nicotine (such as via in-dwelling pumps), phasic exposure to nicotine, which was applied in our study, has been shown to decrease xCT expression (Knackstedt et al., 2009 ). Alternatively, we did not find any significant changes in GLAST, which is primarily located in the cerebellum and retina, expression level in any brain region studied between e-cigarette and air control groups. This is consistent with prior findings which showed that ethanol ingestion for five weeks did not induce any changes in GLAST expression in NAc and PFC in male rats (Alhaddad et al., 2014b; Hakami et al., 2016) . Previous studies found that inhalation of e-cigarettes as well as combustible cigarettes induced significant increase in cotinine concentrations in the plasma and urine (Brazell et al., 1984; Drummond et al., 2016; Ha et al., 2015; Ponzoni et al., 2015; Smith et al., 2015; Xu et al., 2014) . In this study, we further detected nicotine and cotinine concentrations in FC tissues, which provide novel evidence about the distribution of nicotine in e-cigarette vapor into the brain. We found significant nicotine and cotinine concentrations in the brain of animals exposed to nicotine containing e-cigarette vapor, as compared to air control groups. This indicates the ability of inhaled nicotine to cross the blood brain barrier. Previous and our findings may indicate that inhaled nicotine of cigarettes is absorbed into the circulatory system and distributed into central nervous system. Since e-cigarettes and aircontrol groups were placed into the same mesh restraints, the environmental levels of e-cigarette vapor within the fume hood led to very low concentrations of cotinine in the FC of the air control mice.
Conclusion
We conclude here that nicotine delivery via e-cigarette vapor inhalation, using a physiological and clinically relevant exposure method, induced changes in the expression of glial glutamate transporters and nicotinic receptors. Chronic exposure to nicotine through inhalation of e-cigarette vapor containing nicotine increased α-7 nAChR expression in the mesocorticolimbic area. Moreover, e-cigarette exposure also reduced the expression of GLT-1 and xCT, which may lead to high extracellular glutamate concentrations in central reward brain regions. These data demonstrated that nicotine exposure alters glial glutamate transporters as well as nicotinic receptors, which might be key proteins in the development of nicotine dependence.
